The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.
Identifieur interne : 000105 ( Main/Exploration ); précédent : 000104; suivant : 000106The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.
Auteurs : David I. Dolling [Royaume-Uni] ; Ruth L. Goodall [Royaume-Uni] ; Michael Chirara [Zimbabwe] ; James Hakim [Zimbabwe] ; Peter Nkurunziza [Ouganda] ; Paula Munderi [Ouganda] ; David Eram [Ouganda] ; Dinah Tumukunde [Ouganda] ; Moira J. Spyer [Royaume-Uni] ; Charles F. Gilks [Australie] ; Pontiano Kaleebu [Ouganda] ; David T. Dunn [Royaume-Uni] ; Deenan Pillay [Afrique du Sud]Source :
- BMC infectious diseases [ 1471-2334 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Agents antiVIH (usage thérapeutique), Association de médicaments, Charge virale, Estimation de Kaplan-Meier, Femelle, Humains, Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Modèles de hasards proportionnels, Mâle, Ouganda, Pays en voie de développement, Résultat thérapeutique, Surveillance pharmacologique, Zimbabwe, Études de suivi, Études rétrospectives.
- MESH :
- traitement médicamenteux : Infections à VIH.
- usage thérapeutique : Agents antiVIH.
- virologie : Infections à VIH.
- Adulte, Adulte d'âge moyen, Association de médicaments, Charge virale, Estimation de Kaplan-Meier, Femelle, Humains, Modèles de hasards proportionnels, Mâle, Ouganda, Pays en voie de développement, Résultat thérapeutique, Surveillance pharmacologique, Zimbabwe, Études de suivi, Études rétrospectives.
English descriptors
- KwdEn :
- Adult, Anti-HIV Agents (therapeutic use), Developing Countries, Drug Monitoring, Drug Therapy, Combination, Female, Follow-Up Studies, HIV Infections (drug therapy), HIV Infections (virology), Humans, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Retrospective Studies, Treatment Outcome, Uganda, Viral Load, Zimbabwe.
- MESH :
- chemical , therapeutic use : Anti-HIV Agents.
- drug therapy : HIV Infections.
- virology : HIV Infections.
- Adult, Developing Countries, Drug Monitoring, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Retrospective Studies, Treatment Outcome, Uganda, Viral Load, Zimbabwe.
Abstract
Few low-income countries have virological monitoring widely available. We estimated the virological durability of first-line antiretroviral therapy (ART) after five years of follow-up among adult Ugandan and Zimbabwean patients in the DART study, in which virological assays were conducted retrospectively.
DOI: 10.1186/s12879-017-2266-3
PubMed: 28222702
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D83
- to stream PubMed, to step Curation: 000D83
- to stream PubMed, to step Checkpoint: 000D83
- to stream Ncbi, to step Merge: 003E29
- to stream Ncbi, to step Curation: 003E29
- to stream Ncbi, to step Checkpoint: 003E29
- to stream Main, to step Merge: 000105
- to stream Main, to step Curation: 000105
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.</title><author><name sortKey="Dolling, David I" sort="Dolling, David I" uniqKey="Dolling D" first="David I" last="Dolling">David I. Dolling</name><affiliation wicri:level="3"><nlm:affiliation>MRC Clinical Trials Unit at UCL, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Trials Unit at UCL, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Goodall, Ruth L" sort="Goodall, Ruth L" uniqKey="Goodall R" first="Ruth L" last="Goodall">Ruth L. Goodall</name><affiliation wicri:level="3"><nlm:affiliation>MRC Clinical Trials Unit at UCL, London, UK. r.goodall@ucl.ac.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Trials Unit at UCL, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Chirara, Michael" sort="Chirara, Michael" uniqKey="Chirara M" first="Michael" last="Chirara">Michael Chirara</name><affiliation wicri:level="1"><nlm:affiliation>University of Zimbabwe, Harara, Zimbabwe.</nlm:affiliation><country xml:lang="fr">Zimbabwe</country><wicri:regionArea>University of Zimbabwe, Harara</wicri:regionArea><wicri:noRegion>Harara</wicri:noRegion></affiliation></author><author><name sortKey="Hakim, James" sort="Hakim, James" uniqKey="Hakim J" first="James" last="Hakim">James Hakim</name><affiliation wicri:level="1"><nlm:affiliation>University of Zimbabwe, Harara, Zimbabwe.</nlm:affiliation><country xml:lang="fr">Zimbabwe</country><wicri:regionArea>University of Zimbabwe, Harara</wicri:regionArea><wicri:noRegion>Harara</wicri:noRegion></affiliation></author><author><name sortKey="Nkurunziza, Peter" sort="Nkurunziza, Peter" uniqKey="Nkurunziza P" first="Peter" last="Nkurunziza">Peter Nkurunziza</name><affiliation wicri:level="1"><nlm:affiliation>Joint Clinical Research Centre, Kampala, Uganda.</nlm:affiliation><country xml:lang="fr">Ouganda</country><wicri:regionArea>Joint Clinical Research Centre, Kampala</wicri:regionArea><wicri:noRegion>Kampala</wicri:noRegion></affiliation></author><author><name sortKey="Munderi, Paula" sort="Munderi, Paula" uniqKey="Munderi P" first="Paula" last="Munderi">Paula Munderi</name><affiliation wicri:level="1"><nlm:affiliation>Joint Clinical Research Centre, Kampala, Uganda.</nlm:affiliation><country xml:lang="fr">Ouganda</country><wicri:regionArea>Joint Clinical Research Centre, Kampala</wicri:regionArea><wicri:noRegion>Kampala</wicri:noRegion></affiliation></author><author><name sortKey="Eram, David" sort="Eram, David" uniqKey="Eram D" first="David" last="Eram">David Eram</name><affiliation wicri:level="1"><nlm:affiliation>MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.</nlm:affiliation><country xml:lang="fr">Ouganda</country><wicri:regionArea>MRC/UVRI Uganda Research Unit on AIDS, Entebbe</wicri:regionArea><wicri:noRegion>Entebbe</wicri:noRegion></affiliation></author><author><name sortKey="Tumukunde, Dinah" sort="Tumukunde, Dinah" uniqKey="Tumukunde D" first="Dinah" last="Tumukunde">Dinah Tumukunde</name><affiliation wicri:level="1"><nlm:affiliation>MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.</nlm:affiliation><country xml:lang="fr">Ouganda</country><wicri:regionArea>MRC/UVRI Uganda Research Unit on AIDS, Entebbe</wicri:regionArea><wicri:noRegion>Entebbe</wicri:noRegion></affiliation></author><author><name sortKey="Spyer, Moira J" sort="Spyer, Moira J" uniqKey="Spyer M" first="Moira J" last="Spyer">Moira J. Spyer</name><affiliation wicri:level="3"><nlm:affiliation>MRC Clinical Trials Unit at UCL, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Trials Unit at UCL, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Gilks, Charles F" sort="Gilks, Charles F" uniqKey="Gilks C" first="Charles F" last="Gilks">Charles F. Gilks</name><affiliation wicri:level="1"><nlm:affiliation>School of Population Health, University of Queensland, Brisbane, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Population Health, University of Queensland, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Kaleebu, Pontiano" sort="Kaleebu, Pontiano" uniqKey="Kaleebu P" first="Pontiano" last="Kaleebu">Pontiano Kaleebu</name><affiliation wicri:level="1"><nlm:affiliation>Joint Clinical Research Centre, Kampala, Uganda.</nlm:affiliation><country xml:lang="fr">Ouganda</country><wicri:regionArea>Joint Clinical Research Centre, Kampala</wicri:regionArea><wicri:noRegion>Kampala</wicri:noRegion></affiliation></author><author><name sortKey="Dunn, David T" sort="Dunn, David T" uniqKey="Dunn D" first="David T" last="Dunn">David T. Dunn</name><affiliation wicri:level="3"><nlm:affiliation>MRC Clinical Trials Unit at UCL, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Trials Unit at UCL, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Pillay, Deenan" sort="Pillay, Deenan" uniqKey="Pillay D" first="Deenan" last="Pillay">Deenan Pillay</name><affiliation wicri:level="1"><nlm:affiliation>Africa Centre for Health and Population Studies, University of KwaZulu Natal, Durban, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Africa Centre for Health and Population Studies, University of KwaZulu Natal, Durban</wicri:regionArea><wicri:noRegion>Durban</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28222702</idno><idno type="pmid">28222702</idno><idno type="doi">10.1186/s12879-017-2266-3</idno><idno type="wicri:Area/PubMed/Corpus">000D83</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D83</idno><idno type="wicri:Area/PubMed/Curation">000D83</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D83</idno><idno type="wicri:Area/PubMed/Checkpoint">000D83</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D83</idno><idno type="wicri:Area/Ncbi/Merge">003E29</idno><idno type="wicri:Area/Ncbi/Curation">003E29</idno><idno type="wicri:Area/Ncbi/Checkpoint">003E29</idno><idno type="wicri:Area/Main/Merge">000105</idno><idno type="wicri:Area/Main/Curation">000105</idno><idno type="wicri:Area/Main/Exploration">000105</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.</title><author><name sortKey="Dolling, David I" sort="Dolling, David I" uniqKey="Dolling D" first="David I" last="Dolling">David I. Dolling</name><affiliation wicri:level="3"><nlm:affiliation>MRC Clinical Trials Unit at UCL, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Trials Unit at UCL, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Goodall, Ruth L" sort="Goodall, Ruth L" uniqKey="Goodall R" first="Ruth L" last="Goodall">Ruth L. Goodall</name><affiliation wicri:level="3"><nlm:affiliation>MRC Clinical Trials Unit at UCL, London, UK. r.goodall@ucl.ac.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Trials Unit at UCL, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Chirara, Michael" sort="Chirara, Michael" uniqKey="Chirara M" first="Michael" last="Chirara">Michael Chirara</name><affiliation wicri:level="1"><nlm:affiliation>University of Zimbabwe, Harara, Zimbabwe.</nlm:affiliation><country xml:lang="fr">Zimbabwe</country><wicri:regionArea>University of Zimbabwe, Harara</wicri:regionArea><wicri:noRegion>Harara</wicri:noRegion></affiliation></author><author><name sortKey="Hakim, James" sort="Hakim, James" uniqKey="Hakim J" first="James" last="Hakim">James Hakim</name><affiliation wicri:level="1"><nlm:affiliation>University of Zimbabwe, Harara, Zimbabwe.</nlm:affiliation><country xml:lang="fr">Zimbabwe</country><wicri:regionArea>University of Zimbabwe, Harara</wicri:regionArea><wicri:noRegion>Harara</wicri:noRegion></affiliation></author><author><name sortKey="Nkurunziza, Peter" sort="Nkurunziza, Peter" uniqKey="Nkurunziza P" first="Peter" last="Nkurunziza">Peter Nkurunziza</name><affiliation wicri:level="1"><nlm:affiliation>Joint Clinical Research Centre, Kampala, Uganda.</nlm:affiliation><country xml:lang="fr">Ouganda</country><wicri:regionArea>Joint Clinical Research Centre, Kampala</wicri:regionArea><wicri:noRegion>Kampala</wicri:noRegion></affiliation></author><author><name sortKey="Munderi, Paula" sort="Munderi, Paula" uniqKey="Munderi P" first="Paula" last="Munderi">Paula Munderi</name><affiliation wicri:level="1"><nlm:affiliation>Joint Clinical Research Centre, Kampala, Uganda.</nlm:affiliation><country xml:lang="fr">Ouganda</country><wicri:regionArea>Joint Clinical Research Centre, Kampala</wicri:regionArea><wicri:noRegion>Kampala</wicri:noRegion></affiliation></author><author><name sortKey="Eram, David" sort="Eram, David" uniqKey="Eram D" first="David" last="Eram">David Eram</name><affiliation wicri:level="1"><nlm:affiliation>MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.</nlm:affiliation><country xml:lang="fr">Ouganda</country><wicri:regionArea>MRC/UVRI Uganda Research Unit on AIDS, Entebbe</wicri:regionArea><wicri:noRegion>Entebbe</wicri:noRegion></affiliation></author><author><name sortKey="Tumukunde, Dinah" sort="Tumukunde, Dinah" uniqKey="Tumukunde D" first="Dinah" last="Tumukunde">Dinah Tumukunde</name><affiliation wicri:level="1"><nlm:affiliation>MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.</nlm:affiliation><country xml:lang="fr">Ouganda</country><wicri:regionArea>MRC/UVRI Uganda Research Unit on AIDS, Entebbe</wicri:regionArea><wicri:noRegion>Entebbe</wicri:noRegion></affiliation></author><author><name sortKey="Spyer, Moira J" sort="Spyer, Moira J" uniqKey="Spyer M" first="Moira J" last="Spyer">Moira J. Spyer</name><affiliation wicri:level="3"><nlm:affiliation>MRC Clinical Trials Unit at UCL, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Trials Unit at UCL, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Gilks, Charles F" sort="Gilks, Charles F" uniqKey="Gilks C" first="Charles F" last="Gilks">Charles F. Gilks</name><affiliation wicri:level="1"><nlm:affiliation>School of Population Health, University of Queensland, Brisbane, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Population Health, University of Queensland, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Kaleebu, Pontiano" sort="Kaleebu, Pontiano" uniqKey="Kaleebu P" first="Pontiano" last="Kaleebu">Pontiano Kaleebu</name><affiliation wicri:level="1"><nlm:affiliation>Joint Clinical Research Centre, Kampala, Uganda.</nlm:affiliation><country xml:lang="fr">Ouganda</country><wicri:regionArea>Joint Clinical Research Centre, Kampala</wicri:regionArea><wicri:noRegion>Kampala</wicri:noRegion></affiliation></author><author><name sortKey="Dunn, David T" sort="Dunn, David T" uniqKey="Dunn D" first="David T" last="Dunn">David T. Dunn</name><affiliation wicri:level="3"><nlm:affiliation>MRC Clinical Trials Unit at UCL, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Clinical Trials Unit at UCL, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Pillay, Deenan" sort="Pillay, Deenan" uniqKey="Pillay D" first="Deenan" last="Pillay">Deenan Pillay</name><affiliation wicri:level="1"><nlm:affiliation>Africa Centre for Health and Population Studies, University of KwaZulu Natal, Durban, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Africa Centre for Health and Population Studies, University of KwaZulu Natal, Durban</wicri:regionArea><wicri:noRegion>Durban</wicri:noRegion></affiliation></author></analytic><series><title level="j">BMC infectious diseases</title><idno type="eISSN">1471-2334</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-HIV Agents (therapeutic use)</term><term>Developing Countries</term><term>Drug Monitoring</term><term>Drug Therapy, Combination</term><term>Female</term><term>Follow-Up Studies</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (virology)</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Proportional Hazards Models</term><term>Retrospective Studies</term><term>Treatment Outcome</term><term>Uganda</term><term>Viral Load</term><term>Zimbabwe</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Agents antiVIH (usage thérapeutique)</term><term>Association de médicaments</term><term>Charge virale</term><term>Estimation de Kaplan-Meier</term><term>Femelle</term><term>Humains</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (virologie)</term><term>Modèles de hasards proportionnels</term><term>Mâle</term><term>Ouganda</term><term>Pays en voie de développement</term><term>Résultat thérapeutique</term><term>Surveillance pharmacologique</term><term>Zimbabwe</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Developing Countries</term><term>Drug Monitoring</term><term>Drug Therapy, Combination</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Proportional Hazards Models</term><term>Retrospective Studies</term><term>Treatment Outcome</term><term>Uganda</term><term>Viral Load</term><term>Zimbabwe</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Charge virale</term><term>Estimation de Kaplan-Meier</term><term>Femelle</term><term>Humains</term><term>Modèles de hasards proportionnels</term><term>Mâle</term><term>Ouganda</term><term>Pays en voie de développement</term><term>Résultat thérapeutique</term><term>Surveillance pharmacologique</term><term>Zimbabwe</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Few low-income countries have virological monitoring widely available. We estimated the virological durability of first-line antiretroviral therapy (ART) after five years of follow-up among adult Ugandan and Zimbabwean patients in the DART study, in which virological assays were conducted retrospectively.</div></front></TEI><affiliations><list><country><li>Afrique du Sud</li><li>Australie</li><li>Ouganda</li><li>Royaume-Uni</li><li>Zimbabwe</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Dolling, David I" sort="Dolling, David I" uniqKey="Dolling D" first="David I" last="Dolling">David I. Dolling</name></region><name sortKey="Dunn, David T" sort="Dunn, David T" uniqKey="Dunn D" first="David T" last="Dunn">David T. Dunn</name><name sortKey="Goodall, Ruth L" sort="Goodall, Ruth L" uniqKey="Goodall R" first="Ruth L" last="Goodall">Ruth L. Goodall</name><name sortKey="Spyer, Moira J" sort="Spyer, Moira J" uniqKey="Spyer M" first="Moira J" last="Spyer">Moira J. Spyer</name></country><country name="Zimbabwe"><noRegion><name sortKey="Chirara, Michael" sort="Chirara, Michael" uniqKey="Chirara M" first="Michael" last="Chirara">Michael Chirara</name></noRegion><name sortKey="Hakim, James" sort="Hakim, James" uniqKey="Hakim J" first="James" last="Hakim">James Hakim</name></country><country name="Ouganda"><noRegion><name sortKey="Nkurunziza, Peter" sort="Nkurunziza, Peter" uniqKey="Nkurunziza P" first="Peter" last="Nkurunziza">Peter Nkurunziza</name></noRegion><name sortKey="Eram, David" sort="Eram, David" uniqKey="Eram D" first="David" last="Eram">David Eram</name><name sortKey="Kaleebu, Pontiano" sort="Kaleebu, Pontiano" uniqKey="Kaleebu P" first="Pontiano" last="Kaleebu">Pontiano Kaleebu</name><name sortKey="Munderi, Paula" sort="Munderi, Paula" uniqKey="Munderi P" first="Paula" last="Munderi">Paula Munderi</name><name sortKey="Tumukunde, Dinah" sort="Tumukunde, Dinah" uniqKey="Tumukunde D" first="Dinah" last="Tumukunde">Dinah Tumukunde</name></country><country name="Australie"><noRegion><name sortKey="Gilks, Charles F" sort="Gilks, Charles F" uniqKey="Gilks C" first="Charles F" last="Gilks">Charles F. Gilks</name></noRegion></country><country name="Afrique du Sud"><noRegion><name sortKey="Pillay, Deenan" sort="Pillay, Deenan" uniqKey="Pillay D" first="Deenan" last="Pillay">Deenan Pillay</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000105 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000105 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28222702
|texte= The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28222702" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |